Abstract
Polypharmacy is an important aspect of medication management and particularly affects elderly and chronically ill people. Patients with dementia, Parkinson’s disease (PD), or multiple sclerosis (MS) are at high risk of multi medication due to their complex symptomatology. Our aim was to provide an overview of different definitions of polypharmacy and to present the current state of research on polypharmacy in patients with dementia, PD, or MS. The most common definition of polypharmacy in the literature is the concomitant use of ≥5 medications (quantitative definition approach). Polypharmacy rates of up to >50% have been reported for patients with dementia, PD, or MS, although MS patients are on average significantly younger than those with dementia or PD. The main predictor of polypharmacy is the complex symptom profile of these neurological disorders. Potentially inappropriate medication (PIM), drug-drug interactions, poor treatment adherence, severe disease course, cognitive impairment, hospitalisation, poor quality of life, frailty, and mortality have been associated with polypharmacy in patients with dementia, PD, or MS. For patients with polypharmacy, either the avoidance of PIM (selective deprescribing) or the substitution of PIM with more suitable drugs (appropriate polypharmacy) is recommended to achieve a more effective therapeutic management.
Keywords: Polypharmacy, dementia, Parkinson's disease, multiple sclerosis, potentially inappropriate medication, medication management.
Current Pharmaceutical Design
Title:Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Volume: 27 Issue: 38
Author(s): Niklas Frahm*, Michael Hecker and Uwe Klaus Zettl
Affiliation:
- Department of Neurology, Neuroimmunology Section, Rostock University Medical Center, Gehlsheimer Str. 20, 18147, Rostock,Germany
Keywords: Polypharmacy, dementia, Parkinson's disease, multiple sclerosis, potentially inappropriate medication, medication management.
Abstract: Polypharmacy is an important aspect of medication management and particularly affects elderly and chronically ill people. Patients with dementia, Parkinson’s disease (PD), or multiple sclerosis (MS) are at high risk of multi medication due to their complex symptomatology. Our aim was to provide an overview of different definitions of polypharmacy and to present the current state of research on polypharmacy in patients with dementia, PD, or MS. The most common definition of polypharmacy in the literature is the concomitant use of ≥5 medications (quantitative definition approach). Polypharmacy rates of up to >50% have been reported for patients with dementia, PD, or MS, although MS patients are on average significantly younger than those with dementia or PD. The main predictor of polypharmacy is the complex symptom profile of these neurological disorders. Potentially inappropriate medication (PIM), drug-drug interactions, poor treatment adherence, severe disease course, cognitive impairment, hospitalisation, poor quality of life, frailty, and mortality have been associated with polypharmacy in patients with dementia, PD, or MS. For patients with polypharmacy, either the avoidance of PIM (selective deprescribing) or the substitution of PIM with more suitable drugs (appropriate polypharmacy) is recommended to achieve a more effective therapeutic management.
Export Options
About this article
Cite this article as:
Frahm Niklas *, Hecker Michael and Zettl Klaus Uwe, Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease, Current Pharmaceutical Design 2021; 27 (38) . https://dx.doi.org/10.2174/1381612827666210728102832
DOI https://dx.doi.org/10.2174/1381612827666210728102832 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Complications: An Update on Pathobiology and Therapeutic
Strategies
Current Diabetes Reviews Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Correlation between Serum 25 hydroxy vitamin D level and plasminogen activator inhibitor 1 in type 2 diabetic patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application
Current Vascular Pharmacology Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevention of Gestational Diabetes Mellitus (GDM) and Probiotics: Mechanism of Action: A Review
Current Diabetes Reviews Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses The HIV Life Cycle: Multiple Targets for Antiretroviral Agents
Drug Design Reviews - Online (Discontinued) Inherited Renal Diseases
Current Pediatric Reviews Medicinal Plants with Multiple Effects on Cardiovascular Diseases: A Systematic Review
Current Pharmaceutical Design Malaria in Children - Prevention and Management
Infectious Disorders - Drug Targets HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy